In subsequent years, several antibodies targeting PD-1/PD-L1 have been approved by the FDA, including pembrolizumab (PD-1) for metastatic melanoma and a subset of non-small cell lung cancer (NSCLC) tumors, atezolizumab and durvalumab (PD-L1) for bladder cancer, and nivolumab (PD-1) for several malignancies [14–16]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.